Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
"We are delighted with the depth and breadth of the data available on our lead compound, AT-101, at this important scientific conference" said mel
Sorensen, MD, CEO of Ascenta Therapeutics. "The clinical utility of AT-101 is being explored in several major tumor types and treatment regimens, wit...
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
...o demonstrate broad anti-cancer activity in pre-clinical models, including synergy with other agents, by targeting a specific apoptotic pathway," said mel
Sorensen, MD, CEO of Ascenta Therapeutics. "On the basis of these encouraging data, we plan to submit an Investigational New Drug (IND) application t...
Oxygen Biotherapeutics, Inc. Expands Board of Directors
...ckground also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc.
"I'm very pleased that mel
has agreed to join our board," said Chris J. Stern, company chairman and CEO. "He has the business acumen and experience in the pharmaceutical industr...
Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers
...s IntraLase and Visumax. The recent FDA approval of the Carl Zeiss Meditec mel
80 marks the first approval of an entirely new laser platform in 3 years. ...g the Anamed lens for farsightedness; a consultant for Carl Zeiss and their mel
80 excimer laser, Visumax femtosecond laser, Zeiss anterior chamber scan, a...
Campus Celebrates Historic Milestone
...uests included US Senator Elizabeth H. Dole, US Senator
Richard M. Burr, US Congressman Robin C. Hayes, US Congressman J. Howard
Coble, US Congressman mel
Watt, Lieutenant Governor Beverly E. Perdue, NC
Secretary of State Elaine Marshall, along with former Governors James B.
Hunt, Jr. and James G. Martin...
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Inc. (OTC Bulletin Board: LIXT), announces the appointment of mel
M.D. to the company's Board of Directors.
Dr. Sorensen is curre...ed that Dr. Sorensen has joined the Lixte
Biotechnology board of directors. mel
is internationally recognized for his
expertise in clinical oncology and in...
Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
... General of the United States (2002-2006),
President of Canyon Ranch Institute and Distinguished Professor of Public
Health, The University of Arizona mel
and Enid Zuckerman College of Public
Health. "We hope this expanded vaccination recommendation will strongly
encourage Americans to get an annual infl...
Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
-- Mark Tracy, Senior Director, Pharmaceutical Operations, Alnylam Pharmaceuticals
-- RoseAnn Price, Alliance Management, Amgen
Sorensen, M.D., President & CEO, Ascenta Therapeutics, Inc.
-- Ahsan Awan, JD, MBA, CRCP, Global CINRG, Inc.
-- Gur Roshwalb, MD, VP & Senior ...
Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
...homas Fogarty, M.D., cardiovascular surgeon and founder of Crux
Schatz, CEO of Crux states, "We have had very encouraging
results from both... FDA to initiate its pivotal IDE study. For additional information contact mel
Schatz, Crux Biomedical, at
(650) 851-2332, ext. 38, or mschatz@cruxbiomed...
Examples of Electro-Transfected Eukaryotic and Prokaryotic Cells
..., hystiocytic lymphoma
Human, V79, skin cells, fibroblasts
Hybrid, mouse/human, A9 fibroblast
Hybrid, rat/mouse, mel
Monkey, kidney (COS-1, COS-7, CV-1, Vero)
Mouse, 3T3, embryo
Mouse, 32d, myeloma